Joy Bessenger
Directeur Financier/CFO chez TRELLUS HEALTH PLC
Postes actifs de Joy Bessenger
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| TRELLUS HEALTH PLC | Directeur Financier/CFO | 18/09/2023 | - |
Historique de carrière de Joy Bessenger
Anciens postes connus de Joy Bessenger
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| IMV INC. | Investor Relations Contact | 01/09/2021 | 11/06/2022 |
deCODE genetics, Inc.
 deCODE genetics, Inc. Pharmaceuticals: GenericHealth Technology deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland. | Public Communications Contact | 26/06/2009 | - |
Formation de Joy Bessenger
| University of South Florida | Undergraduate Degree |
Statistiques
Internationale
| Islande | 2 |
| Canada | 2 |
| Etats-Unis | 2 |
Opérationnelle
| Public Communications Contact | 1 |
| Investor Relations Contact | 1 |
| Undergraduate Degree | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 2 |
| Technology Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| IMV INC. | Health Technology |
| TRELLUS HEALTH PLC | Technology Services |
| Entreprise privées | 1 |
|---|---|
deCODE genetics, Inc.
deCODE genetics, Inc. Pharmaceuticals: GenericHealth Technology deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland. | Health Technology |
- Bourse
- Insiders
- Joy Bessenger
- Expérience